CRISPR Therapeutics (CRSP) director granted 13,000 options at $51.84 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG director Christian Rommel received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market purchase or sale.

According to the vesting terms, the options will vest and become exercisable in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rommel Christian

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 13,000 options Exercise price: $51.84 per share Expiration date: June 5, 2036 +2 more

5 metrics

Options granted 13,000 options Stock Option (Right to Buy) granted on June 5, 2026

Exercise price $51.84 per share Conversion or exercise price for 13,000 options

Expiration date June 5, 2036 Option expiration for director grant

Post-grant derivative holdings 13,000 options Total derivative securities following transaction

Vesting start June 30, 2026 First monthly installment vests subject to continued service

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Shares, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

vest and become exercisable financial

"the options will vest and become exercisable in 12 equal monthly installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 05:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rommel Christian

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

MASSACHUSETTS

02127

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$51.84	06/05/2026		A		13,000		⁽¹⁾	06/05/2036	Common Shares	13,000	$0	13,000	D

Explanation of Responses:

1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

	/s/ Elizabeth Ryland Waldinger	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did CRISPR Therapeutics (CRSP) director Christian Rommel report in this Form 4?

Christian Rommel reported receiving a grant of stock options for 13,000 common shares. These options are a compensation-related award, not an open-market transaction, and give him the right to buy CRISPR Therapeutics shares at a fixed exercise price in the future.

How many CRISPR Therapeutics (CRSP) options did Christian Rommel receive and at what exercise price?

Christian Rommel received stock options for 13,000 common shares at an exercise price of $51.84 per share. This means he can choose to buy up to 13,000 shares at $51.84, regardless of the market price, once the options vest and become exercisable.

What is the vesting schedule for Christian Rommel’s CRISPR Therapeutics (CRSP) stock options?

The options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting, spreading vesting over roughly one year.

When do Christian Rommel’s CRISPR Therapeutics (CRSP) stock options expire?

The stock options granted to Christian Rommel expire on June 5, 2036. After that expiration date, any unexercised options become worthless, so he must choose whether to exercise vested options before that long-term deadline if conditions are favorable.

Is Christian Rommel’s CRISPR Therapeutics (CRSP) Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant of options, not a stock purchase or sale. The transaction code is “A” for a grant, award, or other acquisition, reflecting compensation. No open-market buying or selling of CRISPR Therapeutics common shares occurred in this reported transaction.

How many CRISPR Therapeutics (CRSP) derivative securities does Christian Rommel hold after this grant?

Following the reported grant, Christian Rommel holds 13,000 stock options as derivative securities. These options each relate to one common share and are held directly. The filing does not show additional derivative positions beyond this newly granted award in the reported data.